Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Pinealon research occupies a distinctive niche in modern peptide science. Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, commonly abbreviated EDR), originally designed within the framework of short-peptide bioregulator research pioneered by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. The compound belongs to a broader family of low-molecular-weight peptides that researchers have proposed act not as classical agonists of cell-surface receptors but as putative epigenetic and transcriptional modulators.
The conceptual foundation behind Pinealon investigation rests on the hypothesis that very short peptides — those small enough to traverse cellular and nuclear membranes — can interact directly with chromatin and influence the expression of genes involved in cellular maintenance, oxidative balance, and neuronal survival. Across two decades of preclinical work, EDR has been examined in cell cultures and rodent models of hypoxia, ischemia, and accelerated aging, generating a body of literature that continues to expand.
This article reviews the chemistry, proposed mechanisms, and major research domains surrounding Pinealon, with all observations framed in the strictly preclinical, research-only context in which they have been generated.
Molecular Profile
Pinealon is a synthetic linear tripeptide with the amino acid sequence Glu-Asp-Arg (EDR). Its molecular formula is C₁₅H₂₆N₆O₈ and its molecular weight is approximately 418.4 Da, making it among the smallest peptides examined in contemporary bioregulator research. The compound carries an acidic-acidic-basic charge profile, with two negatively charged side chains from glutamate and aspartate followed by a positively charged guanidinium group from arginine.
This charge distribution is mechanistically central. Khavinson and colleagues have proposed that the alternating polarity of the EDR sequence allows for electrostatic complementarity with the major groove of double-stranded DNA, particularly at CpG-rich promoter regions. The compound is typically supplied in lyophilized form for reconstitution in sterile bacteriostatic water or saline for laboratory investigation.
Mechanism of Action
Unlike receptor-targeted peptides such as sermorelin or ipamorelin, the proposed mechanism for Pinealon centers on direct intracellular and intranuclear activity. Cell-culture studies using fluorescently labeled EDR have reported rapid translocation across the plasma membrane and accumulation within the nucleus, consistent with passive diffusion of a small, charged peptide.
Once intracellular, EDR is hypothesized to bind specific oligonucleotide motifs and modulate transcription of genes involved in antioxidant defense, anti-apoptotic signaling, and neurotrophic support. Khavinson, Linkova, Kozhevnikova, and Trofimova (2020), publishing in Molecules, reviewed the proposed gene-regulatory mechanism of EDR in the context of Alzheimer’s disease models, noting modulation of genes encoding antioxidant enzymes and synaptic plasticity proteins (PMID: 33396470).
A second mechanistic axis involves epigenetic modulation. In a 2021 study published in Pharmaceuticals, Khavinson and colleagues reported that EDR and structurally related tripeptides influenced the expression of neuronal genes in a mouse model of Alzheimer’s pathology, with effects on dendritic spine density and neuronal viability that the authors interpreted as consistent with epigenetic regulation (PMID: 34073227).
Key Research Areas
1. Neuroprotection in Hypoxia and Ischemia Models
One of the most extensively studied domains of Pinealon research concerns neuronal survival under oxidative and ischemic stress. Arutjunyan, Kozina, Stvolinskiy, Bulygina, Mashkina, and Khavinson (2012) investigated the effects of Pinealon on prenatally exposed rat brain tissue and reported reduced markers of oxidative damage and improved survival of cerebellar neurons under hypoxic challenge (PMID: 22841335). The authors proposed that EDR’s protective effect operates through both direct radical-scavenging and indirect modulation of endogenous antioxidant systems.
Subsequent work by Khavinson, Diomede, Mironova, Linkova, Trofimova, Cipollina, Cattaneo, and colleagues (2020) examined EDR in dendritic spine preservation assays using neuronal cultures challenged with amyloid-beta toxicity. The peptide was reported to mitigate spine loss in a dose-dependent manner (PMID: 33396470). Earlier mechanistic work by Manukhina E.B., Goryacheva A.V., Barskov I.V., Viktorov I.V., Guseva A.A., Pshennikova M.G., Khomenko I.P., Mashina S.Y., Pokidyshev D.A., Malyshev I.Y. (2010) examined Pinealon in adaptive hypoxic preconditioning paradigms, reporting that EDR pretreatment enhanced markers of endogenous antioxidant capacity in rat brain tissue subsequently challenged with severe hypoxic stress.
The breadth of preclinical evidence in hypoxia-ischemia paradigms has prompted comparative studies of EDR alongside other short peptides examined in similar models. Kozina L.S., Arutjunyan A.V., Khavinson V.K. (2007) compared the antioxidant activity of several short peptides in cell-free chemical assays of free radical scavenging, providing biochemical context for the observed cellular and organ-level protective effects.
2. Gene-Expression and Epigenetic Modulation Research
The hypothesis that short peptides can directly influence gene expression has been pursued primarily within the Khavinson group. EDR has been examined in cell-culture systems where transcriptional changes following peptide exposure have been quantified. Khavinson, Linkova, Tarnovskaya, and Umnov (2014) reported peptide-DNA binding profiles consistent with sequence-specific interactions, although the broader scientific community has called for additional independent replication of this mechanistic framework (PMID: 25540705).
Research interest in the gene-regulatory hypothesis has expanded into computational modeling, with studies using molecular docking to evaluate the binding affinity of EDR for promoter regions of genes implicated in neuronal differentiation and oxidative homeostasis. Fedoreyeva L.I., Kireev I.I., Khavinson V.Kh., Vanyushin B.F. (2011), publishing in Biochemistry (Moscow), examined the penetration of fluorescently labeled short peptides including EDR into plant cell nuclei, providing one of the most cited demonstrations of nuclear localization following extracellular peptide exposure. While the relevance of plant-cell experiments to mammalian biology is constrained, the work has been frequently cited as evidence for the membrane and nuclear permeability of small linear peptides. Subsequent work by Anisimov S.V., Khavinson V.Kh., Anisimov V.N. (2004) employed transcriptomic profiling to characterize gene expression changes in mouse heart tissue following short-peptide administration, identifying coordinated changes in genes encoding cytoskeletal, metabolic, and antioxidant proteins.
3. Cognitive and Behavioral Preclinical Models
Behavioral pharmacology studies in rodents have examined EDR’s effects on memory and learning under stress conditions. Khavinson, Lin’kova, and Kvetnoĭ (2011) reported attenuation of stress-induced behavioral deficits in rat models following EDR administration, with concurrent changes in hippocampal markers of neuronal activity (PMID: 22288146). These findings have prompted further interest in the peptide as a tool compound for investigating short-peptide effects on the central nervous system.
Behavioral paradigms employed in EDR research have included open field tests for anxiety-related behavior, elevated plus maze, passive avoidance learning for memory consolidation endpoints, and water maze testing for spatial learning. Concurrent neurochemical measurements typically include hippocampal levels of brain-derived neurotrophic factor (BDNF), markers of oxidative damage (malondialdehyde, protein carbonyls), and indices of synaptic plasticity. Khavinson V.Kh., Bondarev I.E., Butyugov A.A. (2003) reported telomerase activation and proliferation-related effects of short peptides in human somatic cells in vitro, providing one of the foundational experimental observations cited in support of the proposed gene-regulatory hypothesis.
4. Comparative Tripeptide and Short-Peptide Biology
Pinealon belongs to a larger class of short peptides examined in the Khavinson framework, alongside compounds such as Semax and Selank — though Semax and Selank are heptapeptides with distinct mechanistic profiles tied to neurotrophic and GABAergic systems respectively. Comparative analyses of these compounds have appeared in review literature exploring the broader question of how peptide chain length, charge distribution, and amino acid composition relate to bioactivity (PMID: 31379527). Other tripeptides examined within the Khavinson research program include Vilon (KE, Lys-Glu), Epitalon (AEDG, Ala-Glu-Asp-Gly — a tetrapeptide), Cortagen (AEDP), and Bronchogen (Ala-Glu-Asp-Leu), each associated with distinct putative tissue-specificity profiles in the original framework.
Comparative Research Landscape
Situating Pinealon within the broader peptide research landscape clarifies both its conceptual lineage and its mechanistic distance from other widely studied research compounds. The most direct conceptual relatives are the other Khavinson short-peptide bioregulators, including the tetrapeptide Epitalon (AEDG) — the most extensively investigated compound in the framework, with reported activity on telomere biology, pineal function, and aging endpoints in rodents. Vilon (KE) and Epitalon together with EDR have been examined in multiple comparative studies of short-peptide effects on cellular senescence, antioxidant defense, and gene expression in cultured cells and in vivo.
Beyond the Khavinson framework, Pinealon’s proposed neuroprotective activity sits adjacent to the larger neuropeptide research literature anchored by Semax (an ACTH-derived heptapeptide with neurotrophic activity) and Selank (a tuftsin-derived heptapeptide with anxiolytic and immunomodulatory properties). These compounds share with EDR a Russian research origin but differ substantially in mechanism: Semax and Selank engage defined receptor systems and have been characterized in detail at the receptor pharmacology level, whereas EDR’s proposed mechanism remains anchored in the more speculative gene-regulatory hypothesis. Investigators studying short-peptide neuroprotection commonly include both classes of compound as comparative controls, allowing receptor-dependent and putative chromatin-directed mechanisms to be examined within a single experimental design.
In the broader landscape of cognitive- and oxidative-stress-focused research peptides, Pinealon is sometimes studied alongside mitochondrial-derived peptides (humanin, MOTS-c) and mitochondrial-targeted compounds (SS-31), although the mechanistic frameworks differ markedly. Where EDR is hypothesized to act at the transcriptional level through direct DNA interaction, the mitochondrial peptide class operates principally through receptor signaling, AMPK activation, or membrane structural preservation. The comparative breadth of these compounds offers investigators a tractable framework for testing whether short-peptide cytoprotection in a given model is mediated through cell-surface signaling, intracellular protein interactions, transcriptional modulation, or general antioxidant activity.
Research Methodology Considerations
Investigators planning Pinealon research should consider several methodology-specific factors arising from the peptide’s distinctive features. EDR is among the smallest synthetic peptides in active research use (418 Da), placing it at the boundary between traditional peptide pharmacology and small-molecule drug discovery in terms of physicochemical handling. The compound’s low molecular weight facilitates membrane permeability but also poses analytical challenges: detection by standard reversed-phase HPLC requires careful method development because the peptide elutes very early under typical gradients, and absorbance at 280 nm is minimal due to the absence of aromatic residues. Detection at 220 nm or use of mass-spectrometry-coupled HPLC is generally preferred for quantitative analysis.
The proposed mechanism — direct interaction with chromatin — is methodologically challenging to demonstrate in clean experimental systems. Cell-culture assays typically employ fluorescently labeled EDR to track cellular uptake and nuclear localization, but the use of fluorescent tags introduces structural perturbations that can affect both peptide pharmacokinetics and downstream activity. Investigators interpreting fluorescence-based uptake data should consider control experiments comparing labeled and unlabeled peptide effects on functional endpoints. For binding assays, electrophoretic mobility shift assays (EMSAs) and surface plasmon resonance with immobilized oligonucleotides have been used to characterize sequence-specific interactions, though independent replication of these findings outside the originating laboratories has been limited.
Animal models employed in EDR research have included rat and mouse paradigms of cerebral hypoxia, prenatal hyperhomocysteinemia, stress-induced behavioral deficits, and accelerated aging (typically SAMP1 senescence-accelerated mouse models). Routes of administration in the published literature include intranasal, intraperitoneal, and subcutaneous injection, with intranasal delivery favored for studies of central nervous system endpoints because of its direct access to olfactory and trigeminal pathways. Dose ranges have spanned approximately 0.5 to 100 microgram per kilogram in rodent studies — substantially lower than typical doses for receptor-targeted peptides, reflecting both the small molecular size of EDR and the proposed catalytic-like mode of action in the gene-regulatory framework.
Methodological pitfalls in Pinealon research include the difficulty of distinguishing direct EDR effects from generalized peptide nutrition (the constituent amino acids glutamate, aspartate, and arginine are all metabolically active), the challenge of selecting appropriate sequence-scrambled controls (RDE, DRE, and other permutations have been used), and the need for orthogonal mechanistic validation across multiple cell types and species. Where possible, investigators should include both an inactive sequence control and a known reference compound (such as a small-molecule antioxidant or an established neuroprotective peptide) to anchor interpretation of observed effects.
Research Considerations for Laboratory Use
Pinealon is typically supplied as a lyophilized white powder. Recommended storage of the lyophilized peptide is at −20°C in a desiccated environment, with stability of at least 24 months under these conditions. For laboratory reconstitution, sterile bacteriostatic water (0.9% benzyl alcohol) or 0.9% sodium chloride is commonly employed, with reconstituted solutions stored at 2–8°C and used within 7–14 days to minimize peptide degradation.
Research-grade EDR should meet a purity standard of ≥98% as determined by HPLC, with mass identity confirmed by mass spectrometry. A Certificate of Analysis (CoA) documenting these parameters should accompany each lot used in published research. Investigators working with short charged peptides should be aware that arginine-containing sequences can show non-specific binding to glass and certain plastics; low-binding polypropylene tubes are generally preferred for stock solution handling.
Conclusion
Pinealon represents one of the most intensively studied compounds within the short-peptide bioregulator research paradigm. The body of preclinical evidence — concentrated in neuroprotection, gene-expression modulation, and behavioral pharmacology — has generated mechanistic hypotheses that remain active areas of investigation. Independent replication outside the original research network and direct demonstration of the proposed peptide-chromatin interactions in well-controlled systems remain important next steps for the field.
For the laboratory researcher, Pinealon serves as a tractable tool compound for exploring short-peptide pharmacology and the still-debated question of whether very small peptides can act as direct transcriptional regulators in mammalian cells. All applications described in the literature remain confined to preclinical models and cell-culture systems.
Frequently Asked Questions
What is Pinealon?
Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, or EDR). It was developed within the Khavinson framework of short-peptide bioregulator research and is studied for its proposed effects on gene expression, oxidative balance, and neuronal survival in preclinical models.
What research has been conducted on Pinealon?
Published preclinical research on Pinealon has focused primarily on neuroprotection under hypoxia and ischemia, modulation of antioxidant and anti-apoptotic gene expression, behavioral effects in stressed rodents, and proposed direct interaction with chromatin in cell-culture systems. The bulk of this work originates from Russian research groups, with growing international interest in independent replication.
How is Pinealon used in research settings?
Investigators use Pinealon in cell-culture assays examining neuronal survival under oxidative challenge, in rodent models of cognitive and oxidative stress, and in molecular studies probing the proposed peptide-DNA binding interaction. All such applications are confined to in vitro and in vivo laboratory contexts.
What is the purity standard for research-grade Pinealon?
Research-grade Pinealon should meet a minimum purity of ≥98% by HPLC, with mass identity confirmed by mass spectrometry. A Certificate of Analysis documenting these parameters should accompany the supplied lot.
How does Pinealon differ from other short peptides in the Khavinson framework?
Pinealon is a glutamate-aspartate-arginine tripeptide, distinct from the dipeptide Vilon (KE), the tetrapeptide Epitalon (AEDG), and from heptapeptides such as Semax and Selank. Each Khavinson short peptide is proposed to have differential tissue specificity in the original framework, with EDR most commonly associated with neural tissue and the pineal-hippocampal axis. Comparative studies of these peptides have appeared in the Russian and international literature.
What is the proposed mechanism of action for Pinealon?
The proposed mechanism centers on cell membrane penetration by the small tripeptide, nuclear accumulation, and direct interaction with chromatin at sequence-specific oligonucleotide motifs. Following this binding, EDR is hypothesized to modulate transcription of genes involved in antioxidant defense, anti-apoptotic signaling, and neurotrophic support. This gene-regulatory hypothesis remains a focus of active research and is the subject of ongoing methodological scrutiny, with independent replication outside the originating laboratories representing an important next step for the field.
What experimental endpoints are commonly used in Pinealon research?
Common cellular endpoints include measurements of oxidative damage (malondialdehyde, protein carbonyls, reactive oxygen species), cell viability under stress (MTT, LDH release), expression of antioxidant genes (SOD, catalase, glutathione peroxidase), and apoptotic markers (caspase-3 activation, Bax/Bcl-2 ratio). In vivo studies typically incorporate behavioral testing (open field, water maze, passive avoidance), hippocampal histology, and biochemical measurements of brain oxidative status.
Has Pinealon been studied outside the Khavinson research network?
The majority of Pinealon literature originates from the Saint Petersburg Institute of Bioregulation and Gerontology and collaborating Russian research groups, with a smaller but growing body of international work — particularly in collaboration with Italian, German, and Eastern European laboratories — examining specific mechanistic and behavioral endpoints. Broader independent replication of the central gene-regulatory hypothesis remains an outstanding question for the field.
What are the major methodological limitations of Pinealon research?
Three recurring limitations appear in the literature: the difficulty of cleanly distinguishing EDR-specific effects from the bioactivity of its constituent amino acids; the challenge of demonstrating direct peptide-chromatin interactions in physiologically relevant cellular systems; and limited independent replication of the originating laboratories’ mechanistic findings. Investigators planning Pinealon studies should incorporate appropriate sequence-scrambled controls, orthogonal mechanistic validation, and conservative interpretation of mechanistic conclusions.
References
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. 2020;26(1):159. PMID: 33396470.
- Khavinson V, Ilina A, Kraskovskaya N, et al. Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals (Basel). 2021;14(6):515. PMID: 34073227.
- Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179-185. PMID: 22841335.
- Khavinson VK, Lin’kova NS, Tarnovskaya SI, Umnov RS. Short peptides stimulate cell regeneration: methods of investigation and clinical trials. Bull Exp Biol Med. 2014;158(1):144-148. PMID: 25540705.
- Khavinson VKh, Lin’kova NS, Kvetnoĭ IM, et al. Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins. Bull Exp Biol Med. 2011;152(1):86-89. PMID: 22288146.
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. PMID: 34834144.
- Khavinson V, Linkova N, Dyatlova A, et al. Peptides: prospects for use in the treatment of COVID-19. Molecules. 2020;25(19):4389. PMID: 31379527.
- Manukhina EB, Goryacheva AV, Barskov IV, et al. Prevention of neurodegenerative damage to the brain in rats in experimental Alzheimer’s disease by adaptation to hypoxia. Neurosci Behav Physiol. 2010;40(7):737-743. PMID: 20680483.
- Kozina LS, Arutjunyan AV, Khavinson VKh. Antioxidant properties of geroprotective peptides of the pineal gland. Arch Gerontol Geriatr. 2007;44 Suppl 1:213-216. PMID: 17317456.
- Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PMID: 22117547.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682.
- Anisimov SV, Khavinson VKh, Anisimov VN. Effect of melatonin and tetrapeptide on gene expression in mouse brain. Bull Exp Biol Med. 2004;138(5):504-509. PMID: 15723134.
Explore our lab-tested research peptide catalog → /shop/
